ICONIQ Capital LLC Makes New $4.35 Million Investment in Neumora Therapeutics, Inc. $NMRA

ICONIQ Capital LLC purchased a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 2,559,090 shares of the company’s stock, valued at approximately $4,350,000.

A number of other institutional investors also recently bought and sold shares of the business. Johnson & Johnson purchased a new position in shares of Neumora Therapeutics during the second quarter worth approximately $3,144,057,000. Perceptive Advisors LLC acquired a new position in shares of Neumora Therapeutics in the 1st quarter valued at $9,953,000. Siren L.L.C. raised its position in Neumora Therapeutics by 35.1% in the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after purchasing an additional 2,209,039 shares during the last quarter. GSA Capital Partners LLP raised its position in Neumora Therapeutics by 392.6% in the 4th quarter. GSA Capital Partners LLP now owns 534,044 shares of the company’s stock valued at $956,000 after purchasing an additional 425,633 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Neumora Therapeutics during the 3rd quarter worth $31,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Neumora Therapeutics

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 91,690 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00. Following the transaction, the insider owned 48,750 shares of the company’s stock, valued at approximately $73,125. This trade represents a 65.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have sold 453,833 shares of company stock valued at $701,219. Corporate insiders own 26.94% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Royal Bank Of Canada reduced their target price on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Mizuho dropped their price target on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, June 18th. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Needham & Company LLC reduced their price objective on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Finally, Weiss Ratings cut Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Neumora Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $6.57.

Neumora Therapeutics Price Performance

NMRA opened at $1.63 on Monday. Neumora Therapeutics, Inc. has a 12 month low of $0.83 and a 12 month high of $3.65. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 4.50. The stock has a market cap of $306.28 million, a P/E ratio of -1.33 and a beta of 2.75. The stock’s 50 day moving average price is $1.60 and its 200 day moving average price is $2.11.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. As a group, research analysts predict that Neumora Therapeutics, Inc. will post -0.85 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.